Business Context and Reporting Period
Sunshine Biopharma Inc., a small business issuer incorporated in Colorado with principal offices in Montreal, Canada, filed this Form 8-K on June 14, 2011. The report details the entry into a material definitive agreement to advance the company's lead compound, Adva-27a (difluoro-etoposide).
Key Financial Metrics
This filing does not contain standard financial statements, revenue, profit, cash flow, or debt metrics. The only financial figure disclosed is the estimated cost of the new agreement.
- Estimated Agreement Cost: Approximately $1,650,000.
- Payment Terms: Pay-as-you-go basis.
Material Changes
On June 14, 2011, the company entered into a Clinical Trials Agreement with The Jewish General Hospital (JGH), a center of McGill University. This agreement represents a material change in the company's operational scope, initiating preclinical studies and Phase I clinical trials for Adva-27a under the directorship of Dr. Gerald Batist at the Segal Cancer Centre.
Outlook, Risks, and Unusual Items
Agreement Terms: The agreement is effective for three years from the date of signing, with provisions for extension upon project completion subject to mutual written consent. Either party may terminate the agreement with 30 days' written notice.
Management Commentary: The company intends to utilize JGH's comprehensive cancer research facilities, including a Clinical Research Unit, Tissue Repository, and GMP Cell Preparation Facility, to advance its lead compound.
Risks: The filing does not explicitly list risk factors, though the pay-as-you-go nature of the $1.65 million cost implies ongoing cash flow requirements dependent on the progress of the trials.
Investor Verification Checklist
- Verify the company's current cash position to ensure it can fund the estimated $1,650,000 in pay-as-you-go costs.
- Review the full text of the Research Agreement (Exhibit 10.5) for specific milestones and termination clauses.
- Confirm the status of Adva-27a in prior preclinical stages to assess the likelihood of successful Phase I progression.
- Check for any subsequent filings regarding the actual drawdown of funds against the estimated agreement cost.